Next 10 |
home / stock / nevpf / nevpf news
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Abliva AB (publ) (NEVPF) is expected to report for Q4 2023
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q4 GAAP EPS of -SEK0.15. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study &...
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ) has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. The companies entered into a License Agreement in 2004. More news on: NeuroVive Pharmaceutical AB, Healthcare stocks news, Read...
LUND, Sweden , Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License A...
- Continued Progress in KL1333 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. ...
Mitochondrial medicine probably isn’t the last thing your family talked about over dinner, but it may be the key to dealing with some very difficult medical conditions. NeuroVive Pharmaceutical AB (OTCQX: NEVPF) is a niche biotech company that is working on novel solutions to serious me...
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q2 GAAP EPS of -SEK0.14. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
Neurovive Pharm Ab Ord Website:
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Abliva AB (publ) (NEVPF) is expected to report for Q4 2023